Trabeculectomy with Mitomycin C in Refractory Glaucoma Associated with Nonnecrotizing Anterior Scleritis
Published in: Ocular Immunology and Inflammation Dec 2009, Vol. 17, No. 6: 420–422
Theresa A. Williams, MBBCh (Hons), BSc (Hons), MRCOphth, Freda Sii, MBBS, Mark Chaing, MBBS, Philip I. Murray, PhD FRCS. FRCOphth, and Peter Shah, BSc (Hons), MB ChB, FRCOphth
Birmingham and Midland Eye Centre, Birmingham, West Midlands, UK
In the initial publication, the incorrect abstract was published. The correct abstract for this paper is as follows:
Abstract
We report a case of refractory secondary-glaucoma associated with scleritis managed successfully with Mitomycin-C augmented trabeculectomies and preoperative transscleral cyclodiode laser (TSCL). Intraocular pressures (IOPs) were uncontrolled on maximal medical therapy (70mmHgOU). Primary emergency TSCL was performed using reduced parameters whilst optimal immunosuppression was achieved. Uncomplicated elective secondary MMC-trabeculectomies (MMC 0.2mg/ml) were later performed. Over four years postoperative follow-up IOPs have remained within normal range without IOP-lowering medication or bleb manipulations (IOP range 7-14mmHgOU). No scleral melt, scleromalacia or scleritic episodes have occurred postoperatively. This case illustrates that MMC-trabeculectomy and TSCL can be used safely and effectively with appropriate immunosuppression in scleritis-associated secondary glaucoma.